Skip to main content
BC Innovations
Feature Story

A Broad Repertoire

Janssen and its collaborators mine the TCR repertoire to intercept autoimmunity

By Karen Tkach, Staff Writer

Johnson & Johnson wants to halt disease progression in at-risk but pre-symptomatic individuals - a strategy it's calling "disease interception" - but faces the challenge of how to monitor whether a treatment is working in a preventive paradigm. Janssen immunologists are exploring emerging technologies to assess TCR repertoires in patients, which it believes will provide an early read on autoimmune diseases and drug responses well before symptoms emerge.

The pharma is tapping into biotechs and academics to help build its strategy, and forming collaborations with a primary focus on rheumatoid arthritis (RA).

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.